Clinical stage biopharmaceutical company specialized in preserving vascular integrity in life-threatening conditions such as sepsis and septic shock
Location: Germany, Brandenburg, Hennigsdorf
Employees: 11-50
Total raised: $55.23M
Founded date: 2009
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.11.2020 | - | $26.31M | - |
| 26.11.2018 | - | $28.92M | Wellington... |
Mentions in press and media 13
| Date | Title | Description |
| 04.05.2026 | Brandenburg Kapital - News about Adrenomed AG | Hennigsdorf/Berlin - april 2024. AdrenoMed AG, a company focused on the integrity and barrier function of blood vessels (vascular integrity), announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its... |
| 04.04.2023 | Startup Showcase: Adrenomed: Rescuing Vascular Integrity to Save Lives | Adrenomed is a clinical-stage biopharmaceutical company based in Berlin, Germany. The company’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Adrenomed’s unique... |
| 02.12.2021 | Adrenomed Receives Positive EMA Scientific Advice for Further Clinical Development of Adrecizumab in Septic Shock | DGAP-News: Adrenomed AG / Key word(s): Miscellaneous Adrenomed Receives Positive EMA Scientific Advice for Further Clinical Development of Adrecizumab in Septic Shock 02.12.2021 / 11:30 The issuer is solely responsible for the content of th... |
| 30.08.2021 | Adrenomed: Participation in Upcoming Scientific and Industry Events | DGAP-News: Adrenomed AG / Key word(s): Conference Adrenomed: Participation in Upcoming Scientific and Industry Events 30.08.2021 / 16:57 The issuer is solely responsible for the content of this announcement. Adrenomed Announces Participatio... |
| 05.01.2021 | Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO | Adrenomed AG, the vascular integrity company, announced today that its Supervisory Board has appointed Dr. Wolfgang Baiker as Chief Executive Officer (CEO) effective January 1, 2021. |
| 30.11.2020 | HBM HEALTHCARE INVESTMENTS AG PRESS RELEASE : Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update | DGAP-News: Adrenomed AG / Key word(s): Financing Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update 2020-11-30 / 10:30 The issuer is solely responsible for the co... |
| 30.11.2020 | Adrenomed : closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update | DGAP-News: Adrenomed AG / Key word(s): Financing Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update 30.11.2020 / 10:30 The issuer is solely responsible for the co... |
| 30.11.2020 | PRESS RELEASE : Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update | DGAP-News: Adrenomed AG / Key word(s): Financing Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update 2020-11-30 / 10:30 The issuer is solely responsible for the co... |
| 26.09.2019 | Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock | Adrenomed announced today the successful completion of patient enrollment in the proof-of-concept Phase II trial, AdrenOSS-2, evaluating Adrecizumab in patients with early septic shock. Adrecizumab is a first-in-class antibody targeting the... |
| 29.08.2019 | Adrenomed Supervisory Board appoints Jens Schneider-Mergener as CEO & Jens Zimmermann (CMO) joins the Executive Board | Adrenomed announced today that its Supervisory Board has appointed two new members of the Executive Board. Dr. Jens Schneider-Mergener is CEO effective August 1, 2019 and Dr. Jens Zimmerman (CMO) joined the Executive Board effective July 1,... |
Show more